Hangzhou Alltest Biotech (688606.SH) released a pre-increase forecast, with an expected net profit of 278 million to 298 million yuan in 2024, a year-on-year increase of 53.95% to 65.03%.

Hangzhou Alltest Biotech (688606.SH) announced that the company is expected to achieve a net profit attributable to owners of the parent company of 278-298 million yuan in 2024, compared to the same period last year (statutory disclosure data), an increase of 97.4238-117.4238 million yuan, a year-on-year increase of 53.95% to 65.03%. During the reporting period, the company continued to focus on the POCT sub-sector of the in vitro diagnostics industry, effectively grasping market demand, continuously promoting product and service innovation, deepening market expansion strategies. At the same time, the company strengthened internal refined management, improved operational efficiency and cost control capabilities, and took multiple measures to jointly promote steady growth in performance.